Quality of life as a prognostic factor for survival in hepatocellular carcinoma. (6th October 2017)

• Record Type: Journal Article
• Authors: Sternby Eilard, Malin; Hagström, Hannes; Mortensen, Kim Erlend; Wilsgaard, Tom; Vagnildhaug, Ola Magne; Dajani, Olav; Stål, Per; Rizell, Magnus
• Is Part Of: Liver international. Volume 38:Number 5(2018)
• Page Start: 885
• Page End: 894
• Publication Date: 2017-10-06
• Subjects: liver cancer -- patient‐reported -- prognostication -- questionnaire; Liver -- Periodicals; Liver -- Diseases -- Periodicals; 616.362
• DOI: 10.1111/liv.13593
• Languages: English
• ISSNs: 1478-3223

Abstract

Abstract: Background & Aims: Prognostication in hepatocellular carcinoma (HCC) is demanding. Not only tumour extent and performance status are to be considered, but also liver function, which is often limiting for both survival itself and for treatment possibilities. This study was conducted to assess whether patient‐reported questionnaires containing general and liver‐specific questions could improve prognostication of survival. Methods: 185 patients with hepatocellular carcinoma in Norway and Sweden were prospectively included. Patients completed the quality‐of‐life questionnaires EORTC QLQ C30 and HCC18, and clinical, radiological and laboratory parameters were registered. Multivariate Cox regression and Harrell's C‐statistics were used to identify the model that best predicted mortality. Results: Quality‐of‐life data were prognostic for overall survival. Fatigue and nutrition scales were prognostic in the multivariable analyses alone and in combination with clinical parameters. The prognostic value of established scoring systems was increased by the addition of QoL data. The best prognostic power was achieved by combining HCC18 nutrition scale with selected background parameters. Conclusion: Quality‐of‐life questionnaires can prognosticate mortality in HCC patients. When combined with established scoring systems, both the general cancer questionnaire EORTC QLQ C30, and the additional liver cancer‐specific HCC18 increased the prognostic accuracy slightly.